Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jchf.2025.102605 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Capturing Totality of Treatment Effects: A Model-Free Approach to Analyzing Multiple Event-Time Data From Heart Failure Studies.
JACC Heart Fail
August 2025
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Electronic address:
A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?
Clin Infect Dis
August 2025
Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Background: With progressive accumulation of knowledge on SARS-CoV-2 infection clinical management, treatment guidelines recommended several options including remdesivir, a broad-spectrum antiviral. Given the evolving nature of coronavirus disease 2019, capturing the totality of scientific evidence from clinical trials and observational studies is critical to inform clinical decision making. We conducted a systematic literature review with meta-analysis to summarize the effectiveness of remdesivir among hospitalized adults.
View Article and Find Full Text PDFBiosimilars and immunogenicity: a matter of concern?
Expert Opin Drug Saf
May 2025
College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates.
Introduction: Biosimilars have transformed treatment modalities across various medical fields such as oncology, rheumatology, and immunology. Despite their potential for reducing healthcare costs, concerns persist regarding their ability to induce an immune response, which could affect efficacy and safety. This review critically evaluates the current evidence on the immunogenicity of biosimilars and discusses the regulatory frameworks guiding their approval and monitoring.
View Article and Find Full Text PDFCaregiver Global Impression Observations from EMBARK: A Phase 3 Study Evaluating Delandistrogene Moxeparvovec in Ambulatory Patients with Duchenne Muscular Dystrophy.
Neurol Ther
February 2025
Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA, 02142, USA.
Introduction: Duchenne muscular dystrophy (DMD) is a rare, progressive, debilitating neuromuscular disease. The early childhood onset and debilitating nature of the disease necessitate decades of caretaking for most patients. Caregivers have a critical role in evaluating patients' physical functioning and/or response to treatment.
View Article and Find Full Text PDFBayesian metamodeling of early T-cell antigen receptor signaling accounts for its nanoscale activation patterns.
Front Immunol
November 2024
School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel.
T cells respond swiftly, specifically, sensitively, and robustly to cognate antigens presented on the surface of antigen presenting cells. Existing microscopic models capture various aspects of early T-cell antigen receptor (TCR) signaling at the molecular level. However, none of these models account for the totality of the data, impeding our understanding of early T-cell activation.
View Article and Find Full Text PDF